Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Monday, 19 June 2017

187,133 Orion Corporation A shares converted into B shares

Orion Oyj    

Published: 09:50 CEST 19-06-2017 /GlobeNewswire /Source: Orion Oyj / : ORNBV /ISIN: FI0009014377


   

ORION CORPORATION      STOCK EXCHANGE RELEASE 19 JUNE 2017 at 10.50 a.m. EEST              

 

 

187,133 Orion Corporation A shares converted into B shares

 

In accordance with Section 3 of the Articles of Association of Orion Corporation, 187,133 A shares have been converted into 187,133 B shares. The conversion has been entered into the Trade Register on 19 June 2017.

 

The total number of shares in Orion Corporation is 141,257,828 which, after the conversion, consists of 37,266,346 A shares and 103,991,482 B shares. The number of votes of the company's shares is after the conversion 849,318,402.

 

 

  

Orion Corporation

 

 

 

Olli Huotari
SVP, Corporate Functions

 

Jari Karlson
CFO

 

 

                                                                       

                                                                       

Contact person:

Terhi Ormio, Vice President, Communications, tel. +358 10 426 4646

 

 

 

Publisher:

Orion Corporation

Communications

Orionintie 1A, FI-02200 Espoo, Finland

Homepage: www.orion.fi

 

 

Orion is a globally operating Finnish pharmaceutical company - a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology and respiratory for which Orion developes inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2016 amounted to EUR 1,074 million and the company had about 3,500 employees. Orion's A and B shares are listed on Nasdaq Helsinki. Founded in 1917, Orion celebrates its centennial anniversary in 2017.

 

 





This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: Orion Oyj, Orionintie 1, PL 65, Espoo 02101, Finland
If you would like to unsubscribe and stop receiving these e-mails click here.